PE20191077A1 - Esteres de oxaborol y sus usos - Google Patents

Esteres de oxaborol y sus usos

Info

Publication number
PE20191077A1
PE20191077A1 PE2019000887A PE2019000887A PE20191077A1 PE 20191077 A1 PE20191077 A1 PE 20191077A1 PE 2019000887 A PE2019000887 A PE 2019000887A PE 2019000887 A PE2019000887 A PE 2019000887A PE 20191077 A1 PE20191077 A1 PE 20191077A1
Authority
PE
Peru
Prior art keywords
oxaborol
methyl
valinate
dihydrobenzo
carbonyl
Prior art date
Application number
PE2019000887A
Other languages
English (en)
Spanish (es)
Inventor
Tsutomu Akama
David Scott Carter
Jason S Halladay
Robert T Jacobs
Yang Liu
Jacob J Plattner
Yong-Kang Zhang
Michael John Witty
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of PE20191077A1 publication Critical patent/PE20191077A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
PE2019000887A 2016-05-12 2017-05-01 Esteres de oxaborol y sus usos PE20191077A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335565P 2016-05-12 2016-05-12
PCT/IB2017/052522 WO2017195069A1 (en) 2016-05-12 2017-05-01 Oxaborole esters and uses thereof

Publications (1)

Publication Number Publication Date
PE20191077A1 true PE20191077A1 (es) 2019-08-20

Family

ID=58699201

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019000887A PE20191077A1 (es) 2016-05-12 2017-05-01 Esteres de oxaborol y sus usos
PE2018002055A PE20190119A1 (es) 2016-05-12 2017-05-01 Esteres de oxaborol y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018002055A PE20190119A1 (es) 2016-05-12 2017-05-01 Esteres de oxaborol y sus usos

Country Status (31)

Country Link
US (4) US10562921B2 (zh)
EP (2) EP3455227A1 (zh)
JP (2) JP6715957B2 (zh)
KR (2) KR102231489B1 (zh)
CN (2) CN109503637B (zh)
AR (2) AR108450A1 (zh)
AU (2) AU2017263785B2 (zh)
BR (2) BR122018076188A2 (zh)
CA (1) CA3023490C (zh)
CL (2) CL2018003187A1 (zh)
CO (1) CO2018012077A2 (zh)
CR (2) CR20180502A (zh)
DK (1) DK3578562T3 (zh)
EA (2) EA036661B1 (zh)
EC (2) ECSP18091065A (zh)
ES (1) ES2882782T3 (zh)
HK (1) HK1258717A1 (zh)
HU (1) HUE056320T2 (zh)
IL (2) IL262453A (zh)
MA (1) MA44968A (zh)
MX (2) MX2018013743A (zh)
NI (2) NI201801172A (zh)
NZ (1) NZ746906A (zh)
PE (2) PE20191077A1 (zh)
PT (1) PT3578562T (zh)
SG (1) SG11201809237RA (zh)
TN (2) TN2019000106A1 (zh)
TW (1) TWI629279B (zh)
UA (2) UA121354C2 (zh)
UY (2) UY37236A (zh)
WO (1) WO2017195069A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
CA3015662A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
EA036661B1 (ru) * 2016-05-12 2020-12-04 Анакор Фармасьютикалс, Инк. Оксабороловые сложные эфиры и способ лечения паразитической инфекции
US11834466B2 (en) 2017-11-30 2023-12-05 5Metis, Inc. Benzoxaborole compounds and formulations thereof
JP2020180170A (ja) * 2019-04-23 2020-11-05 東ソー株式会社 ハロゲン含有ポリエーテルポリオール組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
WO2010045505A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2011019618A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
PL2673281T3 (pl) 2011-02-07 2016-10-31 Zawierające bor wielozasadowe inhibitory pomp usuwających substancje z komórek bakteryjnych oraz ich zastosowania terapeutyczne
CN103857289A (zh) * 2011-10-07 2014-06-11 先正达参股股份有限公司 用于保护有用植物或植物繁殖材料的方法
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
WO2015013318A1 (en) 2013-07-22 2015-01-29 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
AP2016009046A0 (en) 2013-08-09 2016-02-29 Anacor Pharmaceuticals Inc Tricyclic benzoxaborole compounds and uses thereof
US20170000133A1 (en) * 2013-12-23 2017-01-05 Syngenta Participations Ag Benzoxaborole fungicides
US20180244699A1 (en) * 2015-08-17 2018-08-30 Syngenta Participations Ag 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides
EA036661B1 (ru) * 2016-05-12 2020-12-04 Анакор Фармасьютикалс, Инк. Оксабороловые сложные эфиры и способ лечения паразитической инфекции

Also Published As

Publication number Publication date
EP3578562B1 (en) 2021-06-23
IL262453A (en) 2018-12-31
CR20180560A (es) 2019-01-25
US20230132298A1 (en) 2023-04-27
BR122023022427A2 (pt) 2023-12-26
AR113543A2 (es) 2020-05-13
CR20180502A (es) 2018-12-21
UA120999C2 (uk) 2020-03-10
MX2018015410A (es) 2019-05-27
EP3578562A1 (en) 2019-12-11
US11578087B2 (en) 2023-02-14
HK1258717A1 (zh) 2019-11-15
MX2018013743A (es) 2019-05-02
PE20190119A1 (es) 2019-01-17
NZ746906A (en) 2020-06-26
NI201801172A (es) 2019-04-10
CN109503637A (zh) 2019-03-22
EA034415B1 (ru) 2020-02-05
US20210101916A1 (en) 2021-04-08
CA3023490C (en) 2021-06-08
EA201892475A1 (ru) 2019-04-30
BR122018076188A2 (pt) 2019-09-10
US10562921B2 (en) 2020-02-18
UA121354C2 (uk) 2020-05-12
SG11201809237RA (en) 2018-11-29
ECSP19026702A (es) 2019-06-30
CO2018012077A2 (es) 2018-11-22
IL263161A (en) 2018-12-31
TW201808968A (zh) 2018-03-16
UY37236A (es) 2018-01-02
KR102231489B1 (ko) 2021-03-23
CL2018003187A1 (es) 2019-01-11
AU2017263785B2 (en) 2019-10-03
EA201892203A1 (ru) 2019-04-30
JP6715957B2 (ja) 2020-07-01
AU2018264116B2 (en) 2020-03-12
KR20190005982A (ko) 2019-01-16
ECSP18091065A (es) 2019-07-31
KR20190002695A (ko) 2019-01-08
AU2018264116A1 (en) 2018-12-06
US10882872B2 (en) 2021-01-05
US20200017531A1 (en) 2020-01-16
CA3023490A1 (en) 2017-11-16
WO2017195069A1 (en) 2017-11-16
UY37980A (es) 2020-06-30
AR108450A1 (es) 2018-08-22
CL2018003377A1 (es) 2019-01-11
NI201801171A (es) 2019-04-10
JP6715966B2 (ja) 2020-07-01
TN2018000351A1 (en) 2020-06-15
IL263161B (en) 2022-05-01
MA44968A (fr) 2019-03-20
BR112018071931A2 (pt) 2019-02-05
JP2019081770A (ja) 2019-05-30
TWI629279B (zh) 2018-07-11
CN109503637B (zh) 2021-03-16
US20170327519A1 (en) 2017-11-16
EP3455227A1 (en) 2019-03-20
EA036661B1 (ru) 2020-12-04
KR102243775B1 (ko) 2021-04-22
HUE056320T2 (hu) 2022-02-28
AU2017263785A1 (en) 2018-10-25
JP2019520326A (ja) 2019-07-18
DK3578562T3 (da) 2021-07-12
ES2882782T3 (es) 2021-12-02
CN109153688A (zh) 2019-01-04
PT3578562T (pt) 2021-08-05
TN2019000106A1 (en) 2020-10-05

Similar Documents

Publication Publication Date Title
PE20191077A1 (es) Esteres de oxaborol y sus usos
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2015002361A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
NI201600129A (es) Inhibidores de diacilglicerol aciltransferasa 2
NI201800112A (es) Forma polimorfa de n-{6-(2-hidroxipropan-2-il)-2-[2-(metilsulfonil)etil]-2h-indazol-5-il}-6- (trifluorometil)piridin-2-carboxamida
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112019025388A2 (pt) Suplemento de ração animal, composição de ração animal, usos de um suplemento de ração animal, métodos para produzir um suplemento de ração animal e para produzir uma composição de ração animal
ZA201701844B (en) Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii)
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
UY34426A (es) Derivados de heteroarilcarboxamida, procesos de preparación, composiciones y sus usos en agricultura, veterinaria y control de plagas
DK3271015T3 (da) Nk-3-receptorantagonister til terapeutisk eller kosmetisk behandling af overskydende kropsfedt
LT3097085T (lt) Benzoksazinono dariniai, skirti odos ligų gydymui
HUE056094T2 (hu) Növénybetegség elleni szerek felhasználása
DK3402537T3 (da) Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
BR112018017214A2 (pt) preparação contendo esomeprazol
GB2550750A (en) Anthelmintic compounds
FR3052669B1 (fr) Prothese biologique destinee au traitement des hernies parastomales
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
SG11201705655TA (en) Process for restoring responsiveness to medication in tissue of living organisms
ITUB20153642A1 (it) Protesi biologica funzionale per il trattamento del prolasso del pavimento pelvico
ITUA20162607A1 (it) Composizione attiva per il trattamento degli olivi
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis
PE20170200A1 (es) Composicion farmaceutica que combina un anticonvulsivante y un derivado del acido nicotinico